Xencor And Chugai Pharmaceutical Co., Ltd. (Japan) Initiate Partnership For Optimized Antibodies; Chugai Licenses Xencor's XmAb Technology To Enhance Antibody Efficacy
10/19/2005 5:12:04 PM
MONROVIA, Calif.--(BUSINESS WIRE)--Jan. 10, 2005--Xencor today announced a license and collaboration agreement with Chugai Pharmaceutical Co., Ltd. (Chugai) to create monoclonal antibodies with greatly enhanced potency. Chugai will use Xencor's XmAb(TM) technology on Chugai's antibodies against a proprietary cancer target. The XmAb technology consists of a suite of engineered antibody Fc domains that can be applied to any antibody to control the recruitment of the immune system's effector functions and to greatly increase antibody-mediated tumor killing.